Key result
Aggressive early invasive management with GP IIb/IIIa inhibitors provides greater benefit in diabetic NSTE-ACS patients.
Why the study?
Does an early invasive strategy and the use of drug-eluting stents improve outcomes in diabetic patients with non-ST-segment elevation acute coronary syndromes?
Does an early invasive strategy and the use of drug-eluting stents improve outcomes in diabetic patients with non-ST-segment elevation acute coronary syndromes?
Diabetic patients with NSTE-ACS benefit significantly from an early invasive strategy and drug-eluting stents, particularly sirolimus-eluting stents, though these therapies remain underutilized.
Supports aggressive acute-phase care in diabetic NSTE-ACS; leaves open need for confirmatory RCTs.
Diabetic patients with non-ST-segment elevation acute coronary syndromes are at high risk for subsequent cardiovascular events. At the same time, however, they derive greater benefit than non-diabetic counterparts from an aggressive acute-phase management based on platelet glycoprotein IIb/IIIa receptor antagonists and an early invasive strategy. Despite the benefit, these treatment modalities remain underutilized among patients with diabetes mellitus. The widespread use of drug-eluting stents will further improve outcomes in patients with diabetes undergoing early percutaneous revascularization. In this patient population, the sirolimus-eluting stent appears to be superior to the paclitaxel-coated one.
No takes yet. Share an insight, caveat, or question.
Marco Roffi (2005) conducted a review in Diabetic patients with non-ST-segment elevation acute coronary syndromes. Early invasive strategy and platelet glycoprotein IIb/IIIa receptor antagonists was evaluated. An aggressive acute-phase management based on platelet glycoprotein IIb/IIIa receptor antagonists and an early invasive strategy provides greater benefit to diabetic patients with NSTE-ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: